A triple combination of mocetinostat + celecoxib + anti-PD-1 antibody significantly reduced tumor volume, with primary tumor eradication in 3 out of 8 mice, and 62.5% survival at day 60 after tumor implantation (Fig. 4B,D–F). This evidence concerns the gene PDCD1 and neoplasm.